SciTech to Present at 2020 MedInvest Virtual Infectious Diseases and Immunology Conference

GROSSE POINTE, Mich. - June 10, 2020 - PRLog -- SciTech Development announced that it will deliver a corporate presentation and meet with investors at the 2020 MedInvest Virtual Infectious Diseases and Immunology Conference, June 15-17, 2020.
        Earle Holsapple (SciTech President) and Dr. Brian Leyland-Jones (SciTech Chief Medical Officer) will be presenting the company's lead oncology drug ST-001 nanoFenretinide which is being leveraged as a COVID-19 therapeutic. The company's virtual presentation is scheduled for
Date: Monday, June 15, 2020
Time: 1:30 PM (ET)
        Qualified investors can register to attend the virtual conference for free. Visit www.medinvestconferences.com for additional information or call Earle Holsapple at (313) 938-5517 to schedule 1-on-1 virtual meetings which will continue to be held June 15-17, 2020.
        ST-001 nanoFenretinide may offer additional support in the battle against the COVID-19 pandemic. The drug recently demonstrated antiviral activity against SARS-CoV-2; and, published data supports the use of the active agent fenretinide as an anti-inflammatory agent. SciTech is seeking immediate funding to enter a COVID-19 Phase 1 clinical trial that leverages the company's existing FDA approved IND for an oncology indication.

About SciTech Development

SciTech Development, LLC, is a clinical stage specialty pharmaceutical company focused on novel, advanced drug delivery mechanisms for use with cancer therapeutics. SciTech's patented and differentiated drug delivery system, SDV, is a proprietary intravenous, phospholipid-based, nanoparticle product. SDV enables drug assets, such as fenretinide, that are water insoluble, to be distributed through the circulatory system in sufficient quantities and doses to reach the target cells and produce a therapeutic effect while maintaining low toxicity levels. In its primary capacity as an oncology drug development company, SciTech's Investigational New Drug Application (IND) for ST-001 treatment of T-cell non-Hodgkin's lymphoma (NHL) was accepted last December. Additionally, the FDA has granted Orphan Drug Designation status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Solid preclinical and clinical data makes the case for the use of fenretinide in the treatment of additional blood disorders and solid tumors such as small cell lung, breast, pancreatic, neuroblastoma and other cancers. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. Information regarding SciTech's nano formulation technology and ST-001 nanoFenretinide drug product is available from SciTech Development, LLC by calling (313) 938-5517 or at https://www.scitechdevelopment.com/.